Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
JAMA Network Open|November 5, 2025
Perceived Value of Transfusion Access and Hospice Services Among Patients With Blood CancersHari S Raman, Angel M Cronin, Scott F Huntington, et al.
Leukemia & Lymphoma|October 29, 2025
Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive inductionCameron J Hunter, Wei Cheng, Jan Philipp Bewersdorf, et al.
Blood. Red Cells & Iron|May 4, 2026
Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemiaSatoko Ito, Kunal C Potnis, Ding Quan Ng, et al.
American Journal of Hematology|February 22, 2023
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b studyScott F Huntington, Stephen J Schuster, Wei Ding, et al.
The Oncologist|December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective AnalysisSteven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.
Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Integrating 4 Measures to Evaluate Physical Function in Patients with Cancer (In4M): Protocol for a prospective studyGita Thanarajasingam, Paul G Kluetz, Vishal Bhatnagar, et al.
British Journal of Haematology|December 22, 2017
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysisNirav N Shah, Aniko Szabo, Scott F Huntington, et al.
Blood Advances|August 18, 2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohortJackson T Bowers, Jacob Anna, Steven M Bair, et al.
Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Blood|September 27, 2021
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutionsVictor Manuel Orellana-Noia, Daniel R Reed, Ashley Alesia McCook, et al.
Pageof 9